ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Biological: ABT-874Drug: Placebo
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 1465
- Registration Number
- NCT00570986
- Locations
- 🇺🇸
Site Reference ID/Investigator# 7165, Columbus, Ohio, United States
🇺🇸Site Reference ID/Investigator# 6822, Dallas, Texas, United States
🇺🇸Site Reference ID/Investigator# 6712, Philadelphia, Pennsylvania, United States
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 124
- Registration Number
- NCT00548925
- Locations
- 🇺🇸
Site Reference ID/Investigator# 6356, Hollywood, Florida, United States
🇩🇪Site Reference ID/Investigator# 6564, Bad Mergentheim, Germany
🇩🇪Site Reference ID/Investigator# 11202, Mainz, Germany
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 278
- Registration Number
- NCT00528697
- Locations
- 🇺🇸
Site Reference ID/Investigator# 5982, Overland Park, Kansas, United States
🇺🇸Site Reference ID/Investigator# 5981, Northbrook, Illinois, United States
🇺🇸Site Reference ID/Investigator# 5996, Eugene, Oregon, United States
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- Conditions
- Non-hematologic MalignanciesPrimary Peritoneal CancerHepatocellular CarcinomaMetastatic MelanomaOvarian CancerFallopian Tube CancerBreast Cancer
- Interventions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 41
- Registration Number
- NCT00526617
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
- Conditions
- Crohn's Disease
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 5025
- Registration Number
- NCT00524537
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Drug: ABT-869
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 44
- Registration Number
- NCT00517920
- Locations
- 🇸🇬
Site Reference ID/Investigator# 5235, Singapore, Singapore
🇸🇬Site Reference ID/Investigator# 5611, Singapore, Singapore
🇨🇦Site Reference ID/Investigator# 5837, Vancouver, Canada
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: ABT-869 .25 mg/kgDrug: ABT-869 0.10 mg/kg
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 140
- Registration Number
- NCT00517790
- Locations
- 🇺🇸
Site Reference ID/Investigator# 7194, Fountain Valley, California, United States
🇺🇸Site Reference ID/Investigator# 6739, Evanston, Illinois, United States
🇺🇸Site Reference ID/Investigator# 6042, St. Louis, Missouri, United States
Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
- Conditions
- Diabetic NeuralgiaDiabetic NeuropathiesDiabetic Neuropathy, PainfulDiabetic PolyneuropathyNeuralgia, Diabetic
- Interventions
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 280
- Registration Number
- NCT00507936
- Locations
- 🇺🇸
Site Reference ID/Investigator# 6052, Anaheim, California, United States
🇺🇸Site Reference ID/Investigator# 5276, Clearwater, Florida, United States
🇵🇷Site Reference ID/Investigator# 8121, San Juan, Puerto Rico
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
- Conditions
- Chronic Kidney DiseaseLeft Ventricular Hypertrophy
- Interventions
- Drug: placebo
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 227
- Registration Number
- NCT00497146
- Locations
- 🇷🇺
Site Reference ID/Investigator# 7251, Moscow, Russian Federation
🇨🇳Site Reference ID/Investigator# 8228, Taipei, Taiwan
🇷🇴Site Reference ID/Investigator# 8881, Bucharest, Romania
Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- Drug: ABT-869
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 53
- Registration Number
- NCT00486538
- Locations
- 🇺🇸
Site Reference ID/Investigator# 5379, Boston, Massachusetts, United States
🇺🇸Site Reference ID/Investigator# 7193, Sacramento, California, United States
🇺🇸Site Reference ID/Investigator# 5243, Washington, District of Columbia, United States